AstraZeneca PLC
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Wainua (eplontersen) — US product sales by Quarter
Wainua (eplontersen) — US product sales ($M) ($M)
AstraZeneca Wainua (eplontersen) — US product sales: $64M in Q2 2026, up 48.8% from a year earlier.
Where the Q2 2026 figure comes from
“|| Wainua | | 70 | | 58 | | 58 | | 64 | | 50 | | 1 | | n/m | | n/m | | 4 | | n/m | | n/m | | 1 | | n/m | | n/m”
Source: Form 6-K FY2026Q2 Earnings Release ↗
Reported in Form 6-K / 20-F Product Sales Table.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Wainua (eplontersen) — US product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 64 | +48.8% | Form 6-K FY2026Q2 Earnings Release ↗ |
| Q1 2026 | Mar 31, 2026 | 45 | +15.4% | Form 6-K FY2026Q1 Earnings Release ↗ |
| Q4 2025 | Dec 31, 2025 | 67 | +59.5% | Form 6-K FY2025Q4 Earnings Release ↗ |
| Q3 2025 | Sep 30, 2025 | 55 | +139.1% | Form 6-K FY2025Q3 Earnings Release ↗ |
| Q2 2025 | Jun 30, 2025 | 43 | +168.8% | Form 6-K FY2025Q2 Earnings Release ↗ |
| Q1 2025 | Mar 31, 2025 | 39 | +680.0% | Form 6-K FY2025Q1 Earnings Release ↗ |
| Q4 2024 | Dec 31, 2024 | 42 | – | Form 6-K FY2024Q4 Earnings Release ↗ |
| Q3 2024 | Sep 30, 2024 | 23 | – | Form 6-K FY2024Q3 Earnings Release ↗ |
| Q2 2024 | Jun 30, 2024 | 16 | – | Form 6-K FY2024Q2 Earnings Release ↗ |
| Q1 2024 | Mar 31, 2024 | 5 | – | Form 6-K FY2024Q1 Earnings Release ↗ |
Breakdown
What makes up wainua (eplontersen) — US product sales
Cite this data
StockData. (2026). AstraZeneca Wainua (eplontersen) — US product sales ($M), quarterly Q1 2024–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-wainua-us
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.